Literature DB >> 14573756

Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram.

Shine-Gwo Shian1, Yu-Rung Kao, Felicia Ying-Hsiueh Wu, Cheng-Wen Wu.   

Abstract

Cell invasion and angiogenesis are crucial processes in cancer metastasis that require extracellular matrix (ECM) degradation. Proteolytic degradation of the ECM components is a central event of invasion and angiogenesis processes. During these processes, matrix metalloproteinases (MMPs) seem to be primarily responsible for much of the ECM degradation. Disulfiram is frequently used in the treatment of alcoholism and has been reported to possess antiretroviral activity and can eject intrinsic zinc out of human immunodeficiency virus (HIV) nucleocapsid protein. In this report, we show that disulfiram inhibited invasion and angiogenesis in both tumor and endothelial cells at nontoxic concentrations. The 3H-labeled type IV collagen degradation assay suggested that disulfiram has type IV collagenase inhibitory activity, and this inhibition was responsible for blocking invasion and angiogenesis through cell-mediated and non-cell-mediated pathways. However, the mechanisms underlying cell-mediated signal pathways are not fully characterized. Our data demonstrate that the non-cell-mediated pathway is dominant. Thus, disulfiram could directly interact with MMP-2 and MMP-9 and inhibit their proteolytic activity through a zincchelating mechanism. Addition of zinc could reverse the inhibition of invasiveness and collagenase inhibition through disulfiram treatment. This finding implies that MMP-2 and MMP-9 may be the inhibitory targets for a potential disulfiram treatment. These observations raise the possibility clinical therapeutic applications for disulfiram used as a potential inhibitor of metastatic cell invasion and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573756     DOI: 10.1124/mol.64.5.1076

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  28 in total

Review 1.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

2.  Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.

Authors:  Huacheng He; Eleni Markoutsa; Jing Li; Peisheng Xu
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

3.  Disulfiram deregulates HIF-α subunits and blunts tumor adaptation to hypoxia in hepatoma cells.

Authors:  Hye-joon Park; Min-sung Kim; Kumsun Cho; Jang-hyuk Yun; Yong-joon Choi; Chung-hyun Cho
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

4.  Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.

Authors:  Ghali Brahemi; Fathima R Kona; Annalisa Fiasella; Daniela Buac; Jitka Soukupová; Andrea Brancale; Angelika M Burger; Andrew D Westwell
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 5.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

6.  Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.

Authors:  Jianqing Lin; Michael C Haffner; Yonggang Zhang; Byron H Lee; W Nathaniel Brennen; Justin Britton; Sushant K Kachhap; Joong Sup Shim; Jun O Liu; William G Nelson; Srinivasan Yegnasubramanian; Michael A Carducci
Journal:  Prostate       Date:  2010-08-31       Impact factor: 4.104

7.  Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.

Authors:  Ameya Paranjpe; Ruiwen Zhang; Francis Ali-Osman; George C Bobustuc; Kalkunte S Srivenugopal
Journal:  Carcinogenesis       Date:  2013-11-05       Impact factor: 4.944

8.  Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells.

Authors:  Ameya Paranjpe; Kalkunte S Srivenugopal
Journal:  Carcinogenesis       Date:  2013-01-25       Impact factor: 4.944

9.  Enhanced morphological transformation of human lung epithelial cells by continuous exposure to cellulose nanocrystals.

Authors:  E R Kisin; N Yanamala; D Rodin; A Menas; M Farcas; M Russo; S Guppi; T O Khaliullin; I Iavicoli; M Harper; A Star; V E Kagan; A A Shvedova
Journal:  Chemosphere       Date:  2020-02-13       Impact factor: 7.086

Review 10.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.